Wide Variation Seen in Lung Screening False-Positive Rates

Published Date: 14 Aug 2026

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

Read Full News

Latest News

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

Inconclusive BRCA Results Linked to Higher BC Risk

A new study assesses breast and ovarian cancer risk in women who carry a BRCA variant of uncertain significance or have a noninformative negative result.

OA Tied to Arthritis AE Risk in ICI-Treated Patients

In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.

Stem Cell Transplant Linked to Longer Survival in CMML

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Gatekeeping May Reduce Pediatric Cancer Trial Participation

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

Todays Updates

Freeman’s Lobotomy to Deep Brain Stimulation: What Changed?

The history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.

Todays Updates

Freeman’s Lobotomy to Deep Brain Stimulation: What Changed?

The history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.

Latest News

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

A new study assesses breast and ovarian cancer risk in women who carry a BRCA variant of uncertain significance or have a noninformative negative result.

In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

News All Time

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Patients With Early-Onset Cancer Unaware of Infertility Risk

Many patients with early-onset cancer say they were never told that treatments could affect their fertility.

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

Programs offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

Germline Profiling May Improve Risk Stratification in t-MNs

A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.

Body Clock Genes Tied to Prostate Radiotherapy Toxicity

Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?

Gedatolisib Combo Approved for Advanced Breast Cancer

Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.

MGRS Relapse-Free Survival Better With Maintenance Therapy

Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.

Race, Geography Linked to Gaps in Prostate Cancer Care

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

Recommended News For You

For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.

Trump Issues Gag Order for CDC, FDA; Stalled Hearing for RFK Jr.; Sex After Cancer

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

10-year study shows tomosynthesis improves breast cancer detection

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

Year in Review: Chronic Lymphocytic Leukemia

Recommended Articles For You

Clinical Guidance for Survivorship-Focused Cancer Care 

Understanding Verrucous Carcinoma: Symptoms, Diagnosis, and Treatment Options 

Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights 

Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer

2.

More People Than Previously Believed Have Schizophrenia.

3.

Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer

4.

Novel Agent for Chronic GVHD Wins FDA Approval

5.

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?

1.

Clinical Pharmacology of Stromal-Targeted Anticancer Pharmacotherapy

2.

Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research

3.

Metabolic Heterogeneity and Tumor Persistence: Mechanisms, Clinical Implications, and Emerging Strategies

4.

Strategic Standards in Hematology for Specialists

5.

Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

1.

Efficient Management of First line ALK-rearranged NSCLC - Part VII

2.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

3.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

5.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot